103 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Jul 2030

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

2026202720282029203020312032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 204320442045

notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Animal Models and Therapeutic Molecules US 11,564,380

Cited by 23 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.

Ends Jul 2030 · Medium confidence Also notable

Antibodies and Immunocytokines US 10,604,576

Cited by 52 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.

Ends Jul 2036 · High confidence Also notable

Precision Medicine by Targeting PD-L1 Variants for Treatment of Cancer US 9,045,545

Cited by 33 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.

Ends Jul 2034 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Nov 19 to 26, 2026 · next Nov 19
7 fees due Dec 2 to 30, 2026 · next Dec 2
2 fees due Jan 2 to 25, 2027 · next Jan 2
1 fee due Feb 18, 2027
The maintenance fee for Precision Medicine by Targeting PD-L1 Variants for Treatment of Cancer (US 9,109,034) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
2 fees due Mar 12 to 22, 2027 · next Mar 12
3 fees due Apr 3 to 10, 2027 · next Apr 3
3 fees due May 14 to 21, 2027 · next May 14
3 fees due Jul 2 to 23, 2027 · next Jul 2
1 fee due Aug 9, 2027
The maintenance fee for Animal Models and Therapeutic Molecules (US 9,253,965) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
3 fees due Sep 5 to 30, 2027 · next Sep 5
5 fees due Oct 5 to 23, 2027 · next Oct 5
1 fee due Nov 7, 2027
The maintenance fee for FIXaxFX Bispecific Antibody with Common Light Chain (US 11,976,135) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nov 6Assignment recorded on 1 record: McCourt, Matthew John and 9 others to Kymab Limited Recorded Nov 6, 2026, executed Apr 15, 2021. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76661, frame 979.
1 of the patents on this record was granted since Aug 17, 2026

What they patent

The 5 largest of its 37 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Precision Medicine for Cholesterol Treatment	22 in force	to Jul 2034
Transgenic Mouse Homozygous for Chimeric IgH Locus	15 in force	to Aug 2032
Anti-Human OX40L Antibodies	12 in force	to Apr 2035
Targeting Rare Human PCSK9 Variants for Cholesterol Treatment (2013)	6 in force	to Dec 2034
Targeting Rare Human PCSK9 Variants for Cholesterol Treatment (2014)	6 in force	to Jul 2034

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,434,782	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · Medium confidence	In force	Term ends Jul 7, 2030	Medium confidence
US 9,447,177	Transgenic Mouse Homozygous for Chimeric IgH Locus In force Ends no later than Jul 7, 2030 · Medium confidence	In force	Ends no later than Jul 7, 2030	Medium confidence
US 9,504,236	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · High confidence	In force	Term ends Jul 7, 2030	High confidence
US 9,505,827	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · Medium confidence	In force	Term ends Jul 7, 2030	Medium confidence
US 10,064,398	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · Medium confidence	In force	Term ends Jul 7, 2030	Medium confidence
US 10,165,763	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · Medium confidence	In force	Term ends Jul 7, 2030	Medium confidence
US 11,564,380	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · Medium confidence	In force	Term ends Jul 7, 2030	Medium confidence
US 11,606,941	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · High confidence	In force	Term ends Jul 7, 2030	High confidence
US 11,812,731	Animal Models and Therapeutic Molecules In force Term ends Jul 7, 2030 · Medium confidence	In force	Term ends Jul 7, 2030	Medium confidence
US 9,253,965	Animal Models and Therapeutic Molecules In force Term ends Mar 28, 2032 · High confidence	In force	Term ends Mar 28, 2032	High confidence

10 of 103 patents shown.

Pro members see all 103.

Pro members: see all 103 patents

Also on record, not counted in the 103: 8 patents ended · 34 applications pending · 72 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Kymab Limited